% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Joseph:1010687,
      author       = {Joseph, Benjamin Philipp and Weber, Verena and Knüpfer,
                      Lisa and Giorgetti, Alejandro and Alfonso-Prieto, Mercedes
                      and Krauß, Sybille and Carloni, Paolo and Rossetti, Giulia},
      title        = {{L}ow {M}olecular {W}eight {I}nhibitors {T}argeting the
                      {RNA}-{B}inding {P}rotein {H}u{R}},
      journal      = {International journal of molecular sciences},
      volume       = {24},
      number       = {17},
      issn         = {1422-0067},
      address      = {Basel},
      publisher    = {Molecular Diversity Preservation International},
      reportid     = {FZJ-2023-03195},
      pages        = {13127 -},
      year         = {2023},
      abstract     = {The RNA-binding protein human antigen R (HuR) regulates
                      stability, translation, and nucleus-to-cytoplasm shuttling
                      of its target mRNAs. This protein has been progressively
                      recognized as a relevant therapeutic target for several
                      pathologies, like cancer, neurodegeneration, as well as
                      inflammation. Inhibitors of mRNA binding to HuR might thus
                      be beneficial against a variety of diseases. Here, we
                      present the rational identification of structurally novel
                      HuR inhibitors. In particular, by combining chemoinformatic
                      approaches, high-throughput virtual screening, and
                      RNA–protein pulldown assays, we demonstrate that the
                      4-(2-(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)hydrazineyl)benzoate
                      ligand exhibits a dose-dependent HuR inhibition effect in
                      binding experiments. Importantly, the chemical scaffold is
                      new with respect to the currently known HuR inhibitors,
                      opening up a new avenue for the design of pharmaceutical
                      agents targeting this important protein.},
      cin          = {IAS-5 / INM-9},
      ddc          = {540},
      cid          = {I:(DE-Juel1)IAS-5-20120330 / I:(DE-Juel1)INM-9-20140121},
      pnm          = {5241 - Molecular Information Processing in Cellular Systems
                      (POF4-524) / 5252 - Brain Dysfunction and Plasticity
                      (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5241 / G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {37685931},
      UT           = {WOS:001061141200001},
      doi          = {10.3390/ijms241713127},
      url          = {https://juser.fz-juelich.de/record/1010687},
}